Home › Funds › Bellevue Group AG › BSX

Bellevue Group AG position in BSX

BOSTON SCIENTIFIC CORP · Health Care

Bellevue Group AG reported holding 887,650 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q2 2026 13F filing — a position valued at US$37.9M, representing 0.80% of its reported portfolio and ranking #35 among its reported holdings. Bellevue Group AG has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)887.65K sh
Reported value held$37.88M
Portfolio Weight0.80%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's BSX position evolved

Bellevue Group AG first disclosed a stake in BSX in Q3 2023 at 2,646,295 shares (US$139.7M). The position peaked in Q1 2024 at 3,148,676 shares, worth US$215.7M. Across 12 filings, Bellevue Group AG increased the stake 1 time(s), trimmed it 10 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 887,650 shares valued at US$37.9M — a reduction of -579,244 shares quarter over quarter.. Notable position changes include a 39% trim in Q2 2026 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.65M $139.72M New
Q4 2023 3.17M $183.29M Add
Q1 2024 3.15M $215.65M Reduce
Q2 2024 2.57M $197.88M Reduce
Q3 2024 2.45M $205.54M Reduce
Q4 2024 2.14M $190.72M Reduce
Q1 2025 1.95M $196.82M Reduce
Q2 2025 1.77M $189.60M Reduce
Q3 2025 1.66M $162.05M Reduce
Q4 2025 1.56M $148.71M Reduce
Q1 2026 1.47M $92.05M Reduce
Q2 2026 887.65K $37.88M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include Banque Cantonale Vaudoise (US$2.89B), PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has Bellevue Group AG held BSX?

Bellevue Group AG has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Bellevue Group AG's current position in BSX?

As of Q2 2026, Bellevue Group AG holds 887.65K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $37.88M, representing 0.80% of its reported portfolio and ranking #35.

Has Bellevue Group AG been buying or selling BSX?

In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in BSX. The position peaked in Q1 2024 at 3.15M shares.

Which other funds hold BSX?

Other major institutional holders of BSX include Banque Cantonale Vaudoise, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.